Yuka Morikawa
Overview
Explore the profile of Yuka Morikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morikawa Y, Kim J, Li R, Liu L, Liu S, Deshmukh V, et al.
Circulation
. 2024 Oct;
151(1):76-93.
PMID: 39392007
Background: Many specialized cells in adult organs acquire a state of cell cycle arrest and quiescence through unknown mechanisms. Our limited understanding of mammalian cell cycle arrest is derived primarily...
2.
Liu S, Deshmukh V, Meng F, Wang Y, Morikawa Y, Steimle J, et al.
Circulation
. 2024 Aug;
151(1):59-75.
PMID: 39185559
Background: The Hippo pathway effector YAP (Yes-associated protein) plays an essential role in cardiomyocyte proliferation and heart regeneration. In response to physiological changes, YAP moves in and out of the...
3.
Li R, Li X, Morikawa Y, Grisanti-Canozo F, Meng F, Tsai C, et al.
Nat Cardiovasc Res
. 2024 Mar;
3(3):283-300.
PMID: 38510108
After myocardial infarction (MI), mammalian hearts do not regenerate, and the microenvironment is disrupted. Hippo signaling loss of function with activation of transcriptional co-factor YAP induces heart renewal and rebuilds...
4.
Long H, Steimle J, Grisanti Canozo F, Kim J, Li X, Morikawa Y, et al.
Life Sci Alliance
. 2023 Nov;
7(2).
PMID: 38012001
Modulation of the heart's immune microenvironment is crucial for recovery after ischemic events such as myocardial infarction (MI). Endothelial cells (ECs) can have immune regulatory functions; however, interactions between ECs...
5.
Hill M, Kadow Z, Long H, Morikawa Y, Martin T, Birks E, et al.
Nature
. 2022 Jun;
608(7921):181-191.
PMID: 35732239
The heart, the first organ to develop in the embryo, undergoes complex morphogenesis that when defective results in congenital heart disease (CHD). With current therapies, more than 90% of patients...
6.
Aharonov A, Shakked A, Umansky K, Savidor A, Genzelinakh A, Kain D, et al.
Nat Cell Biol
. 2020 Oct;
22(11):1346-1356.
PMID: 33046882
Cardiomyocyte loss after injury results in adverse remodelling and fibrosis, inevitably leading to heart failure. The ERBB2-Neuregulin and Hippo-YAP signalling pathways are key mediators of heart regeneration, yet the crosstalk...
7.
Arai K, Morikawa Y, Ubukata N, Sugimoto K
Hypertens Res
. 2020 Jul;
43(11):1204-1213.
PMID: 32616846
Esaxerenone is a novel selective mineralocorticoid receptor (MR) blocker that was recently approved in Japan to treat hypertension. In phase II and III studies, esaxerenone plus a renin-angiotensin system inhibitor...
8.
Monroe T, Hill M, Morikawa Y, Leach J, Heallen T, Cao S, et al.
Dev Cell
. 2019 Feb;
48(6):765-779.e7.
PMID: 30773489
Specialized adult somatic cells, such as cardiomyocytes (CMs), are highly differentiated with poor renewal capacity, an integral reason underlying organ failure in disease and aging. Among the least renewable cells...
9.
Li L, Tao G, Hill M, Zhang M, Morikawa Y, Martin J
Development
. 2018 Aug;
145(18).
PMID: 30143541
Loss of the paired-like homeodomain transcription factor 2 () in cardiomyocytes predisposes mice to atrial fibrillation and compromises neonatal regenerative capacity. In addition, gain-of-function protects mature cardiomyocytes from ischemic injury...
10.
Ito Y, Ohno K, Morikawa Y, Tomizawa A, Mizuno M, Sugidachi A
Sci Rep
. 2018 Jul;
8(1):9955.
PMID: 29967338
Vasodilator-stimulated phosphoprotein (VASP) is a member of actin regulatory proteins implicated in platelet adhesion. In addition, phosphorylation of VASP is utilised for the assessment of platelet reactivity in patients treated...